Navigation Links
Neuralstem Announces 2012 Financial Results, Provides Clinical Trials Update
Date:3/15/2013

ression patients in our ongoing NSI-189/major depressive disorder (MDD) Phase Ib trial. Dosing has now increased from 40 mg. q.d.(once/day) for 28 days, which had been shown to be well-tolerated and safe in the first cohort, to 40 mg. b.i.d.(twice/day) for 28 days. Dosing of all patients in the second cohort will be completed this month and, pending FDA approval, we will commence dosing the final cohort."

Neuralstem's President and CEO Richard Garr added, "Neuralstem continued to strengthen its patent estate in 2012. Among the highlights, U.S. Patent number 8,236,299 includes claims covering processes for dissociating our neural stem cells from CNS tissue; culturing the cells; expanding the cells in vitro, and transplanting the cells into the spinal cord of a patient to treat a wide array of neurodegenerative conditions, including ALS, chronic and acute spinal cord injury, and stroke. Both the substance and life of this patent (into 2030) are reflective of the Intellectual Property value we are creating in our cell therapy programs. Additionally, during the past 12 months we have executed the first two out-licenses of our spinal platform cell therapy technology."

"Dr. Johe and I would like to extend our continued deep appreciation to our patients, their families and caregivers, our world-class clinical collaborators, and the Neuralstem team for enabling positive, ground-breaking clinical work which has now positioned us to move forward," added Garr.

Business Highlights for 2012 Cellular Therapy: NSI-566 Phase I Clinical Trial in ALS (amyotrophic lateral sclerosis, or Lou Gehrig 's disease) at Emory University Hospital

  • Neuralstem completed the final surgery of its Phase I NSI-566/ALS trial in August. The trial proved the safety of the company's proprietary technology, the cells and proprietary intraspinal surgical procedure. Data presented at the International
    '/>"/>

    • SOURCE Neuralstem, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    0

    GOOD

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. Neuralstem ALS Stem Cell Trial Featured on Fox Atlanta
    2. Neuralstem President and CEO to Update Ongoing ALS and NSI-189/Major Depressive Disorder Trials at 2012 Biotech Showcase
    3. Neuralstem President and CEO to Present at BIO CEO & Investor Conference 2012
    4. Neuralstem Announces Closing of $5.2-Million Registered Direct Offering
    5. Fourteenth Patient Dosed in Neuralstem ALS Stem Cell Trial
    6. Neuralstem CEO to Present at the World Stem Cells and Regenerative Medicine Congress in London
    7. Neuralstem Receives Notice Of Issuance For Patent Covering Human Neural Cell Transplantation For Neurodegenerative Conditions
    8. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
    9. Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
    10. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    11. VaxyGen Assay Services, LLC Announces Launch of Custom Bioassay Services and Operations
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/24/2013)... May 24, 2013 Senomyx , Inc. ... taste science technologies to discover, develop, and commercialize novel ... , Ph.D., the Company,s Vice President, Biology and ... Relations & Corporate Communications, will present an overview of ... 10:25 a.m. Eastern Time (7:25 a.m. Pacific Time) during ...
    (Date:5/24/2013)... 2013 Vestiage, Inc. (stock symbol ... on science-based research and development, sales and marketing ... nutraceuticals, announced today that it is awarding exclusive ... sale of Reluma Skin Illuminating Facial Care. Qualified ... by sending an email to info(at)vestiageinc(dot)com and putting ...
    (Date:5/23/2013)... 2013 Venaxis, Inc. (Nasdaq:   APPY), an ... FDA clearance and commercializing its rapid, protein biomarker-based appendicitis ... an underwritten public offering of 10,000,000 shares of its ... of its common stock at an exercise price of ... of $1.25 per share and related warrant.  Venaxis has ...
    (Date:5/23/2013)... 2013 Patheon Inc ., a ... the global pharmaceutical industry, will host a complimentary webinar ... Testing” on Tuesday, June 4, 2013 at 11 a.m. ... required to comply with regulations for cleaning validation. ... scientific underpinning and little evaluation of risk. Some ...
    Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2
    ... KVISTGAARD, Denmark, September 22 Bavarian,Nordic A/S ... European Cancer Organisation (ECCO), ECCO 15 - 34th ESMO ... data from a Phase II double-blind, prospective randomized,placebo-controlled study ... Dr. Wayne Godfrey, Senior Medical Director, BN,ImmunoTherapeutics. , ...
    ... 22 Micromet, Inc. (Nasdaq: MITI ), a ... cancer, inflammation and autoimmune diseases, today announced the appointment of ... Medical Officer effective November 1, 2009. , ... and has more than 20 years of experience in clinical ...
    ... , SEATTLE, Sept. 22 Cell ... has been added to the NASDAQ OMX Global Biotechnology Index (NASDAQ: ... prior to the market open on September 21, 2009. , ... modified market-capitalization weighted index designed to track the performance of the ...
    Cached Biology Technology:New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 2New and Interesting PROSTVAC(TM) Data Indicate Broad Therapeutic Use in Metastatic Prostate Cancer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 2Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 3Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer 4Cell Therapeutics Added to the NASDAQ OMX Global Biotechnology Index 2
    (Date:5/24/2013)... in the ongoing public health debate is the lack ... nutrient dense. A new study, "Vegetable Cost Metrics ... Penny," published in the journal PLOS ONE , ... values in the produce aisle, providing one of the ... vegetables and delivering one of the most affordable source ...
    (Date:5/24/2013)... studying noise in one French Quarter neighborhood of New ... municipal ordinances, Annette Hurley, PhD, Assistant Professor of Audiology ... Arriaga, a third-year LSUHSC doctor of audiology student, recommend ... hearing health. Their case study is published online in ... Management ., "An important part of an audiologist,s practice ...
    (Date:5/23/2013)... RICHLAND, Wash. Pacific Northwest National Laboratory honored ... and commercialization of intellectual property at PNNL,s annual ... , The Department of Energy national laboratory ... Year for his work developing battery materials that ... to the electrical grid, and reduce the time ...
    Breaking Biology News(10 mins):New research shows that potatoes provide one of the best nutritional values per penny 2Please do try this at home 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2
    ... NY, April 29, 2011Videoscopy, a groundbreaking new ... Journal of Laparoendoscopic & Advanced Surgical ... Ann Liebert, Inc., publishers ( http://www.liebertpub.com ). ... surgical and microinvasive demonstrations of the latest ...
    ... team of scientists has produced an innovative new study of ... April issue of the journal Ecological Applications . ... both of UC Santa Barbara,s Department of Geography. They analyzed ... a study of 3,100 households in the cities of Minneapolis ...
    ... , , , , , , , ... , , , ... which is about one millisecond long. Several fish can be heard in... , ... , , , , , , ...
    Cached Biology News:Groundbreaking minimally invasive surgical videojournal launched by Mary Ann Liebert Inc. 2UCSB urban ecosystem research featured in leading ecology journal 2UCSB urban ecosystem research featured in leading ecology journal 3Jump in communication skills led to species explosion in electric fishes 2Jump in communication skills led to species explosion in electric fishes 3Jump in communication skills led to species explosion in electric fishes 4Jump in communication skills led to species explosion in electric fishes 5Jump in communication skills led to species explosion in electric fishes 6Jump in communication skills led to species explosion in electric fishes 7
    The Holten Horizontal series of laminar airflow work benches offers comfort and ease of use....
    The 891 45° Fixed Angle Rotor is designed to provide aerosol containment and can be removed from a centrifuge (seal entact) and opened under an environmental hood....
    ... with any of UVP's Doc-It systems. When ... 1D Analysis software onto your existing computer. ... functions and enhancement tools. Doc-It 1D Analysis ... algorithms for quick and accurate electrophoresis analysis., ...
    ... compatible with hood installations. ... system for 384-well plates, ... prepares large quantities of ... Wellpro also performs plate ...
    Biology Products: